OncoTargets and Therapy
SCI一区
EI同步收录
月刊
高认可度
更新时间: 浏览量:
期刊基础介绍
OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.
The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.
Specific topics covered by the journal include:
-Novel therapeutic targets and innovative agents
-Novel therapeutic regimens for improved benefit and/or decreased side effects
-Early stage clinical trials
Further considerations when submitting to OncoTargets and Therapy:
-Studies containing in vivo animal model data will be considered favorably.
-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.
-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.
-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Single nucleotide polymorphism (SNP) studies will not be considered.
The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.
Specific topics covered by the journal include:
-Novel therapeutic targets and innovative agents
-Novel therapeutic regimens for improved benefit and/or decreased side effects
-Early stage clinical trials
Further considerations when submitting to OncoTargets and Therapy:
-Studies containing in vivo animal model data will be considered favorably.
-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.
-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.
-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Single nucleotide polymorphism (SNP) studies will not be considered.
期刊核心参数
通讯方式
PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752
涉及的研究方向
BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY
出版国家或地区
ENGLAND
出版语言
English
年文章数
89
PubMed Central (PMC)链接
平均录用比例
较易
CITESCORE
CiteScore SJR SNIP CiteScore排名 7.00 0.818 0.667 学科 分区 排名 百分位 大类:Medicine 小类:Pharmacology (medical) Q1 52 / 275 81% 大类:Medicine 小类:Oncology Q1 87 / 415 79%WOS期刊JCR分区
WOS分区等级:2区| 按JIF指标学科分区 | 收录子集 | JIF分区 | JIF排名 | JIF百分位 |
| 学科:BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | 92/177 |
|
| 学科:ONCOLOGY | SCIE | Q2 | 160/326 |
|
| 按JCI指标学科分区 | 收录子集 | JCI分区 | JCI排名 | JCI百分位 |
| 学科:BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SCIE | Q3 | 101/177 |
|
| 学科:ONCOLOGY | SCIE | Q3 | 194/326 |
|
期刊分区表预警名单
2025年03月发布的2025版:不在预警名单中2024年02月发布的2024版:不在预警名单中
2023年01月发布的2023版:不在预警名单中
2021年12月发布的2021版:预警等级:中
2020年12月发布的2020版:预警等级:中
中科院2025年3月升级版
点击查看中国科学院期刊分区趋势图| 大类学科 | 小类学科 | Top期刊 | 综述期刊 | ||||
|---|---|---|---|---|---|---|---|
| 医学 4区 |
| 否 | 否 |
中科院2023年12月旧的升级版
| 大类学科 | 小类学科 | Top期刊 | 综述期刊 | ||||
|---|---|---|---|---|---|---|---|
| 医学 4区 |
| 否 | 否 |